We thus hypothesized that a composite biomarker incorporating baseline HER2 tissue-based biomarkers in addition to 18F-FDG PET/CT could further improve biomarker performance in patients with early-stage HER2-positive breast cancer undergoing neoadjuvant therapy with HP alone. The gene discussed is ERBB2; the disease is breast carcinoma.